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These findings support the role of cytokines, especially TNFα, in 
depression.
ECT decreased TNFα levels during each ECT session.
Low TNFα levels during the first ECT session predict symptom re-
duction after the treatment.
LIMITATIONS
The number of patients is relatively small.
TNFα levels of normal controls were not available.
Plasma TNFα levels may be affected by anesthesia during ECT 
series.
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Objective: Changes in the tumor necrosis factor- α (TNFα) have been associated with 
l-fou7;ru;vvb;7bvou7;uŐ		őĺbm7bm]v1om1;umbm]|_;;==;1|vo=;Ѵ;1|uo1omѴ-
sive therapy (ECT) on the TNFα level have been contradictory. The aim was to exam-
ine the immediate and long- term changes in the TNFα level and their associations with 
vlr|olu;71|bombmr-|b;m|vb|_		7ubm]$ĺ
MethodĹ$_;v|7bm1Ѵ7;7ƒƏr-|b;m|vb|_		ĺ$_;bu$α levels were meas-
u;7-|0-v;Ѵbm;-m7Ƒ-m7Ɠ_u-=|;u|_;=buv|ķ=b=|_-m7Ѵ-v|$v;vvbomĺ	;ru;vvb;
vlr|olv ;u; -vv;vv;7 b|_ |_; om|]ol;uŊv0;u] 	;ru;vvbom !-|bm] "1-Ѵ;
Ő	!"őĺ
Results: The TNFα level decreased from baseline to the 2- and 4- hr measurements. 
There was a correlation between the first ECT session TNFα levels and the relative 
vlr|olu;71|bom-11ou7bm]|o|_;	!"v1ou;-=|;u|_;$v;ub;vĺo|_|_;=buv|
(baseline) ECT and 4- hr TNFα levels were lower in responders than in 
nonresponders.
Conclusion: ECT consistently induced a decrease in the TNFα level after each studied 
v;vvbomĺѴo$α level at the first ECT appeared to predict a symptom reduction. 
These findings suggest that TNFαlb]_|_-;-uoѴ;bm|_;r-|_o];m;vbvbm		-m7
in the mechanism of action of ECT.
  +)!	 "
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ƐՊ |Պ$!	&$
Electroconvulsive therapy (ECT) is considered to be the most effi-
1-1bov |u;-|l;m| =ou v;;u;l-fou 7;ru;vvb;7bvou7;u Ő		ő Ő&
ECT Review Group, 2003). Thus, the main indications for ECT are se-
;u;rv1_o|b1		-m7|u;-|l;m|u;vbv|-m1;bmr-|b;m|vb|_		
Ől;ub1-mv1_b-|ub1vvo1b-|bomķƑƏƏƐőĺo;;uķ|_;l;1_-mbvlo=
action of ECT remains obscure.
Tumor necrosis factor- α (TNFα) is a proinflammatory cytokine that 
has been considered to be expressed in the brain only in response to 
pathological stimuli. However, TNFα as well as some other cytokines 
have recently been found to play an active role in neural plasticity and 
m;uo];m;vbvŐ_-buo-ķ-1_-7oŊ(b;bu-ķ	ķş-mfbķƑƏƏƖĸ+bulb-
ş ov_;mķ ƑƏƐƐőĺ $_; 1|ohbm; _ro|_;vbv o= 7;ru;vvbom ruorov;v
that activation of the inflammatory system, which results in increased 
production of proinflammatory cytokines, contributes to the patho-
];m;vbv o= 		 Ő-;vķ ƐƖƖƔőĺ m -mbl-Ѵ lo7;Ѵvķ 1|ohbm; -1|b--
tion has produced depressive symptoms, a decreased hippocampal 
oѴl;ķ-m7ľvb1hm;vv0;_-bouĿ Ő	mmķ"b;u]b;Ѵķş7;;-u;r-bu;ķ
ƑƏƏƔĸ ov_;m ;|-Ѵĺķ ƑƏƏѶĸ -vomķ 1vh;uķ ş ;ѴѴ;ķ ƑƏƐƒőĺ
llmo|_;u-rb|_bm|;uѴ;hbmŊƑoubm|;u=;uomŊα is reportedly asso-




tokine inducers, also cause a depressed mood in healthy individuals 
(Harrison et al., 2009).
Proinflammatory cytokines such as TNFα are associated with the 
actions of mood- relevant neurotransmitters, including the mono-
-lbm;vķ 0 7b==;u;m| r-|_-v ŐbѴѴ;uķ -Ѵ;|b1ķ ş !-bvomķ ƑƏƏƖőĺ
However, the reported associations between TNFα -m7 		 ou
ECT are inconsistent due to different methodologies and variations 
bmv|7rorѴ-|bomvĺm-77b|bomķ0o|_rѴ-vl--m7v;ul$α lev-
;Ѵv_-;0;;mu;rou|;7ĺ";;u-Ѵl;|-Ŋ-m-Ѵv;v_-;u;;-Ѵ;7l-uh-
edly higher concentrations of TNFα in depressed individuals than in 
_;-Ѵ|_1om|uoѴvŐ	oѴ-|b;|-ѴĺķƑƏƐƏĸoѴ7vlb|_ķ!-r-rou|ķşbѴѴ;uķ
ƑƏƐѵĸ-m]ş;;ķƑƏƏƕĸbķoķş-hķƑƏƐƑőĺo;;uķv|7-
ies with no association with changes in the TNFα level and symp-
|olvo=		_-;0;;mr0Ѵbv_;7Ő--r-hovhbķ-|_b;ķ0l;b;uķ
Ѵ;mbvķ ş bbl࢜hbķ ƑƏƐƔĸ -uѴob1ķ ";uu;||bķ (uhb1ķ -u|bm-1ķ ş
-u1bmhoķ ƑƏƐƑĸ+oomķ blķ ;;ķ omķ ş blķ ƑƏƐƑőĺ $_bv -vvo-
1b-|bom _-v 0;;m t;v|bom;7 bm - u;1;m| l;|-Ŋ-m-Ѵvbv Őmbvl-mķ
!-bm7u-mķub==b|_vķş;u-ѴbķƐƖƖƖőĺ|_-v-Ѵvo0;;m_ro|_;vb;7
that the pathophysiological mechanisms of various subtypes of 
		lb]_|7b==;u=uolom;-mo|_;ub|_u;vr;1||o7vu;]Ѵ-|bom
o=|_;bllm;Ŋbm=Ѵ-ll-|ouvv|;lŐ-l;uv;|-ѴĺķƑƏƐƒőĺm;u;-
port suggested that atypical depression is associated with an ele-
vated TNFα Ѵ;;Ѵ Ő-m;Ѵb7;ķ -||;bķ);v|ubmķ $u࢜vhl-mŊ;m7ķ ş
um7bmķ ƑƏƐƐőĺ Ѵ;-|;7 $α levels have also been associated 
b|_vb1b7;-||;lr|v-m77bvvo1b-|b;vlr|olvŐ00-vbķovv;bmbķ
o7-00;umb-ķ v_u-=bķ ş h_om7-7;_ķ ƑƏƐƑĸ bbh ;|-Ѵĺķ ƑƏƐƓőĺ
The nonsteroidal anti- inflammatory drug celecoxib reportedly has 
-0;m;=b1b-Ѵ;==;1|bmr-|b;m|vb|_		-v-m-7f-m|l;7b1-|bom
Őh_om7-7;_;|-ѴĺķƑƏƏƖĸ-u]-u;|-ѴĺķƑƏƐƓĸুѴѴ;u;|-ѴĺķƑƏƏѵőĺ
77b|bom-ѴѴķ1;Ѵ;1ob0u;71;7|_;$α level after an ECT series in 
r-|b;m|vb|_0broѴ-u7bvou7;uŐ	-m|;uķĽommouķ-vomķş;ѴѴ;ķ
2011).
|_-v0;;mru;vl;7|_-|$α, through its induction of indoleam-
bm;ƑķƒŊ7bo];m-v;Ő	őķ-1|b-|;v|_;hmu;mbm;r-|_-ķ_b1_bv
1omvb7;u;7|o0;-vvo1b-|;7b|_ bm=Ѵ-ll-|bom-m77;ru;vvbomĺ 	
catabolizes tryptophan into neuroactive kynurenine metabolites such 
as quinolic acid and 3- hydroxy kynurenine. These tryptophan me-
tabolites are neurotoxic because they are able to generate oxidative 
radicals and act as N- methyl- N- aspartate receptor agonists (Haroon, 
!-bvomķ ş bѴѴ;uķ ƑƏƐƑĸ -;vķ b_-Ѵo-ķ 0;u-ķ ş !bm];Ѵķ ƑƏƐƑĸ
"1_-u1ķ umoķ1_ovhbķ ş)ķ ƑƏƐƑőĺmo|_;ul;|-0oѴb|; o=
kynurenine, kynurenic acid, is considered to have neuroprotective 
ruor;u|b;vŐ-uoom;|-ѴĺķƑƏƐƑĸbm|şblķƑƏƏƒőĺ|_-v0;;mv]-
];v|;7|_-|bmr-|b;m|vb|_7;ru;vvbomķ-1|b-|bomo=	1oѴ7|um
the kynurenine pathway toward the generation of neurotoxic metab-
olites (Guloksuz et al., 2015). ECT was recently reported to increase 
the levels of kynurenic acid, referring to the fact that ECT can alter the 
balance of the kynurenine pathway toward a neuroprotective course 
Ő"1_b;Ѵ;u ;|-Ѵĺķ ƑƏƐѵőĺ u|_;ulou;ķ $ 1-m u;rou|;7Ѵ 7;1u;-v;
quinolic acid levels in patients with treatment- resistant depression 
Ő;v|-7ķ$pmv;|_ķ"|p;mķ&;Ѵ-m7ķşhuv|ķƑƏƏƒőĺѴ|o];|_;uķ|_;v;
findings imply that the mechanism of action of ECT is partly associated 
with the kynurenine pathway, which is induced by TNFα.
"ol;v|7b;v_-;-77u;vv;7|_;-vvo1b-|bom0;|;;m$α and 
$ Őbuv|ķ "rb|;uķb00omķş)bѴѴb-lvķƐƖƖѵĸѴb|l-m;|-Ѵĺķ ƑƏƐƐĸ
Hestad et al., 2003; Rotter et al., 2013; Rush et al., 2016; Zincir, 
|uhķbѴ];mķ1bķş+hv;ѴbuķƑƏƐѵőĺmƑƏƏƒķ;v|-7;|-ѴĺŐѴb|l-m
et al., 2011) reported a decrease in the TNFα level in patients with 
		-Ѵom]b|_1Ѵbmb1-Ѵblruo;l;m|7ubm]-m7-=|;u-m$v;ub;vķ
whereas another study revealed a rapid increase in the TNFα level 
after a single ECT session but no long- term change during the ECT 
v;ub;vŐ!o||;u;|-ѴĺķƑƏƐƒőĺ|_;uv|7b;v_-;=om7mo1_-m];bm|_;
TNFα level during or after the ECT series (First et al., 1996; Hestad 
;|-ѴĺķƑƏƏƒĸ,bm1bu;|-ѴĺķƑƏƐѵőĺu;1;m|v|7u;;-Ѵ;7-7;1u;-v;bm
the TNFα level during and after an ECT series, although the baseline 
TNFα level before ECT was lower in patients than in controls (Rush 
et al., 2016).
ƐĺƐՊ|Պblvo=|_;v|7
The causality of the TNFα level and ECT as well as the association 
between changes in the TNFα level and symptoms during ECT are 
contradictory. The aim of this study was to examine the changes in 
the plasma level of TNFα and their possible associations with symp-
|olu;71|bombmr-|b;m|vb|_		-||_u;;7b==;u;m|v;vvbomv7ubm]
an ECT series. These sessions were included to study the immediate 
and long- term effects of ECT on the TNFα level during an ECT series. 
TNFα was measured from plasma (instead of serum) in order to avoid 
artifact production of TNF alpha during the sampling procedure/clot-
|bm]ruo1;vvŐ7;-];uķou1b;uķ!bfh;uvķu-hh;mķş";=;u|Ŋ-u]oѴbvķ
2009).




v;1|b;Ѵ -7lb||;7 =ou $ |o |_; 	;r-u|l;m| o= v1_b-|uķ
Tampere University Hospital were asked to participate in this study. 
Thirteen of these 49 patients declined, and six patients withdrew 
from the study. Therefore, the study group comprised 30 patients 
ŐƐƑ=;l-Ѵ;ķƐѶl-Ѵ;őĺm-7lbvvbomķ|_;"|u1|u;7Ѵbmb1-Ѵm|;ub;
=ou	"Ŋ(	bvou7;uvŐl;ub1-mv1_b-|ub1vvo1b-|bomķƐƖƖƓő-v
1om71|;7 |o 1om=bul |_; 7b-]movbv bm ;-1_ r-|b;m|ĺ ѴѴ r-|b;m|v
=Ѵ=bѴѴ;7 |_; 	"Ŋ( 7b-]mov|b1 1ub|;ub- =ou 		 Őom|]ol;u ş
Åsberg, 1979), and 14 of them had psychotic symptoms. Nine pa-
|b;m|vv==;u;7=uol-=buv|;rbvo7;o=		ķ-m7|_;		-vu;-
current in 21 patients.
Patients with bipolar depression and major psychiatric disorders 
o|_;u |_-m 		;u; ;1Ѵ7;7ĺ -|b;m|v b|_ ruo]u;vvb; ou]-mb1
brain disorders, epilepsy, inflammatory or autoimmune diseases, and 
alcohol or other substance abuse were also excluded from the study. 
Patients who had undergone ECT within 3 months prior to entry into 
the study were not included.
The mean age of the patients was 57.1 years (standard deviation 
[SD], 17.7; range, 25–85 years). The patients underwent constant 
psychotropic drug treatment throughout the entire ECT period 
(Table 1). Twenty- eight patients in the study were taking a combina-
tion of at least two psychotropic medications, and only two were un-
7;u]obm]lomo|_;u-rĺ;mo7b-;rbm;v;u;7bv1om|bm;7ƐƏ_ouv
before ECT to avoid any effects on the seizure threshold.
The severity of depression was quantified by the Montgomery- 
v0;u] 	;ru;vvbom !-|bm] "1-Ѵ; Ő	!"ő Őom|]ol;u ş ܲv0;u]ķ
1979) in addition to the TNFα level before the first and after the fifth 
and last ECT session.
ѴѴr-|b;m|vruob7;7ub||;mbm=oul;71omv;m|ĺ$_bvv|77;vb]m
was reviewed and approved by the Tampere University Hospital Ethics 
Committee.
ƑĺƑՊ|ՊѴ;1|uo1omѴvb;|_;u-r
;=ou; |_; =buv| $ v;vvbomķ -l;7b1-Ѵ _bv|ou-v o0|-bm;7 -m7 -
physical examination with routine blood examination and electro-
cardiogram was performed. ECT was administered three times a 
;;hb|_-1omv|-m|Ŋ1uu;m|ķ0ub;=ŊrѴv;7;b1;Ő$vr$ul
ƔƏƏƏ ĸ$ourĺķ-h;v;]oķ!ķ&"őĺ$_;v;bu;|_u;v_-
old was titrated during the first treatment, and subsequent treatments 
were administered at 1.5 times the seizure threshold for bilateral 
$ĺ";bu;vo=ƻƑƔv bm7u-|bomom;Ѵ;1|uo;m1;r_-Ѵo]u-r_;u;
7;;l;7 -7;t-|;ĺ = |_; 7u-|bom-v v_ou|;uķ - u;v|blѴ-|bom-v






Mean ± SD 57.1 ± 17.7 71.1 ± 12.2 45.2 ± 17.0
Range 25–85 45–85 25–79
Total number of ECTs
Mean ± SD 10.4 ± 3.6 10.8 ± 4.3 8.2 ± 3,6
Range 5–17 5–17 5–13
Psychotic symptoms 14 7 7
buv|;rbvo7;o=		 9 4 5
!;1uu;m|		 21 13 8
m|b7;ru;vv-m|v
""! 9 3 6
"! 12 5 7
Mirtazapine 12 6 6





Conventional neurolepts 1 0 1
mboѴ|b1v
;mo7b-;rbm;v 21 8 13
Pregabalin 2 2 0
vrbuom; 1 0 1
""!ķ";Ѵ;1|b;v;uo|ombmu;r|-h;bm_b0b|ouĸ"!ķ";uo|ombm-m7mou;rbm;r_ubm;u;r|-h;bm_b0b|ouĺ
$ ƐՊPsychotropic medications of 
r-|b;m|vb|_		7ubm]|_;$v;ub;v
Ɠo=ѶՊ|ՊՊՍ SORRI ET AL.
performed during the same treatment session with a 50% increase in 
the stimulus intensity.
ƑĺƒՊ|Պm;v|_;vb-
m;v|_;vb- -v bm71;7 b|_ l;|_o_;b|-Ѵ Őbmb|b-Ѵ 7ov; o= Ɛl]ņ
kg), and muscle relaxation was achieved with succinylcholine (initial 
dose of 0.5 mg/kg). The patients were ventilated with 100% oxygen 
until resumption of spontaneous respiration. Physiological monitor-
ing during the treatment included pulse oximetry, blood pressure, 
electrocardiography, one- channel electroencephalography and elec-
|uolo]u-r_ĺѴѴ r-|b;m|v;u; |u;-|;7b|_ v|-m7-u70bѴ-|;u-Ѵ Ő0b-
frontotemporal) ECT. The number of treatments ranged from 5 to 
17 (10.4 ± 3.6 [mean ± SD]). ECT treatment was discontinued on 
the basis of clinical judgment if the patient was either in remission 
Ő	!"v1ou;o=ƽƐƏőķoumo=u|_;ublruo;l;m|-vu;1ou7;77u-
bm]|_;Ѵ-v||o$v;vvbomvĺm=b;r-|b;m|vķ|_;=b=|_$v;vvbom
was the last (not included in the last ECT session data).
ƑĺƓՊ|ՊѴoo7v-lrѴbm]
$_;0Ѵoo7v-lrѴbm]-vv|ub1|Ѵv|-m7-u7b;7ĺѴoo7-v7u-m0;-
fore ECT (baseline) and 2 and 4 hr after ECT at the first, fifth, and 
Ѵ-v|v;vvbomvķ-m7	$Ŋ|u;-|;7rѴ-vl--vv;r-u-|;7-m7v|ou;7-|
ƴѶƏŦ m|bѴ -m-Ѵ;7ĺ $_; 1om1;m|u-|bom o= $α was determined 
by enzyme- linked immunosorbent assay with commercial reagents 
Ő -m|bhbm;"ĸ!ş	"v|;lvuor;ķ|7ĺķ0bm]7omķ&őĺ$_;7;-
tection limit and interassay coefficient of variation were 0.25 pg/ml 
and 3.3%, respectively.
ƑĺƔՊ|Պ"|-|bv|b1-Ѵl;|_o7v
r-bu;7Ŋv-lrѴ;t- test was used to analyze changes between the TNFα 
level at different measurement points: baseline vs. 2 hr, baseline vs. 




u;vrom7;uvĽ -m7momu;vrom7;uvĽ $α levels were performed using 
the Mann–Whitney U- test because of the non- normal distribution of 
the TNFαѴ;;Ѵvĺom=;uuomb1ouu;1|bom-vv;7bm|_;1ouu;Ѵ-|bom
calculation by setting the limit of statistical significance to 0.05/9, 
|_-|bvķ07bb7bm]0|_;ml0;uo=|;v|vĺm-ѴѴo|_;u|;v|vķ|_;Ѵ;;Ѵ
of significance was set at p < ĺƏƔĺ"r;-ul-mĽv1ouu;Ѵ-|bom1o;==b1b;m|v
were used in the exploratory analyses for selecting statistically sig-
nificant or trend level (p < .1) correlating explanatory variables for the 
regression model to predict dichotomized response, in addition to the 
bm1Ѵ7;71om=om7bm]-ub-0Ѵ;v-];-m7];m7;uĺѴo]bv|b1u;]u;vvbom
lo7;Ѵ-v v;7 |o ru;7b1| - 7b1_o|olb;7 u;vromv;ĺ m |_;lo7;Ѵķ






The plasma levels of TNFα during ECT series are presented in Table 2. 
These levels consistently decreased from baseline (before ECT) to 2 hr 
during the first (p < .001), fifth (p < .001), and last (p = .007) ECT ses-
sions. The plasma TNFα level also decreased from baseline to 4 hr dur-
ing every ECT session (p < .001, p < .001, and p = .001, respectively). 
No significant changes were found in the TNFα level between the 
2- and 4- hr measurements. When comparing the baseline TNFα level 
among the first, fifth, and last ECT sessions, no significant changes 
were found in the whole study group (Figure 1).
ubou |o |_; =buv| $ v;vvbomķ |_; l;-m 	!" v1ou; -v




line TNFα level at the first ECT session (prior to ECT series), the 
2- and 4- hr TNFα levels, and the relative (%) symptom reduction 
-=|;u |_;$ v;ub;v -v u;=Ѵ;1|;70 |_;	!" v1ou; ŐρƷƴĺƔѶѶķ
p = .001; ρƷƴĺƔƕƓķ p = .001; ρƷƴĺѵƏƏķ p < .001, respectively) 
(Table 3). Low TNFα concentrations and symptom reduction accord-
bm] |o |_; 	!" v1ou; ;u; bm|;uu;Ѵ-|;7 Őb]u;Ƒőĺ $_;v; 1ou-
relations were inconsistent in subsequent ECT sessions (fifth and 
last). The TNFα level at both the first ECT session (baseline) and 4 hr 
ECT Measurement N Mean Standard deviation Range
First -v;Ѵbm; 30 1.65 0.56 2.42
2 hr 30 1.42 0.47 1.91
4 hr 30 1.34 0.43 1.88
Fifth -v;Ѵbm; 30 1.64 0.45 2.23
2 hr 30 1.41 0.39 1.76
4 hr 30 1.48 0.46 1.82
Last -v;Ѵbm; 25 1.59 0.43 1.70
2 hr 25 1.42 0.39 1.68
4 hr 25 1.39 0.43 2.00
$ ƑՊMeans, standard deviations, 
and ranges of plasma TNFα levels during 
ECT series (pg/ml)
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were lower in responders (50% symptom reduction) than in nonre-
sponders (p = .035 and p = .006, respectively). The dichotomized re-
sponse had a statistically significant or trend level (p < .1) correlation 
with smaller number of ECT treatments (ρƷƴĺƒƑķ p = .084) and 
with lower baseline TNFα levels (ρƷƴĺƒƖķp = .032). The best fit-
ting logistic regression model for predicting the dichotomized re-
sponse (p = ĺƏƒőbm1Ѵ7;7$-Ѵr_-0-v;Ѵbm;-Ѵ;Ő!ƷƏĺƑƏķƖƔѷ
 ƏĺƏƓŋƐĺƐƔķp = ĺƏƕő -m7 ml0;u o= $ |u;-|l;m|v Ő!ƷƏĺƕѵķ
ƖƔѷƏĺƔƕŋƐĺƏƑķp = .07) as explanatory variables. This model ex-
plained 31.0% of the outcome variance (Nagelkerke R square); the 
sensitivity for response was 90.9% and specificity 50%. Gender and 
age had nonsignificant correlations with the dichotomized response. 
Neither gender nor age had any predictive effect on the response, 
and omitting these variables from the model did not change the pre-
dictive values.
No correlations were found between clinical parameters (e.g., du-
ration of convulsions, heart rate variability, or changes in blood pres-
sure during ECT) and the TNFα level or clinical outcome.
ƓՊ |Պ	"&""
The most interesting finding in the present study was that a low TNFα 
level at the first ECT (0, 2, and 4 hr) appeared to predict a reduction in 
symptoms. No similar correlations were found during subsequent ses-
sions. No findings suggesting associations between a low TNFα level 
and symptom reduction during ECT have been reported in previous 
studies (First et al., 1996; Fluitman et al., 2011; Hestad et al., 2003; 
!o||;u;|-ѴĺķƑƏƐƒĸ!v_;|-ѴĺķƑƏƐѵĸ,bm1bu;|-ѴĺķƑƏƐѵőĺ=u;rѴb1-|;7
in the future studies, this finding supports the role of TNFα in the 
r-|_o];m;vbvo=		-m7bm|_;l;1_-mbvlo=-1|bomo=$ĸb|l-
also guide the selection of treatment modalities for patients with se-
;u;		ĺ$_;u;_-v0;;m-b7;-ub-|bombm$α levels in differ-
ent studies. However, some of these have reported similar ranges of 
plasma TNFα levels in depressed patients compared to those in the 
ru;v;m|v|7Ő	ol;;|-ѴĺķƑƏƏƖĸன	omo-m;|-ѴĺķƑƏƐƒőĺ
The decrease in the plasma TNFα level after each session was a 
consistent finding in the present study. This was observed in every 
studied session between the baseline measurement and both the 2- 
and 4- hr measurements. The effect of ECT on the TNFα level appears 
to be transitory because the TNFα level returned to the basic level 
 &! ƐՊPlasma TNFα levels at first, 
fifth, and last ECT sessions in patients with 
		
$ ƒՊCorrelations between plasma TNFα levels and relative 
Őѷővlr|olu;71|bombmr-|b;m|vb|_		7ubm]$
ECT Measurement rho p
First -v;Ѵbm; ƴĺƔƔѶ .001*
2 hr ƴĺƔƕƓ .001*
4 hr ƴĺѵƏƏ .001*
Fifth -v;Ѵbm; ƴĺƑѶƒ .130
2 hr ƴĺƐƖƐ .312
4 hr ƴĺƑѶƓ .128
Last -v;Ѵbm; ƴĺƔƏƒ .10
2 hr ƴĺƒƖƏ .054
4 hr ƴĺƓƔƔ .022
*"b]mb=b1-m|-=|;uom=;uuombĽv1ouu;1|bomĺ
 &! ƑՊFirst ECT 4- hr TNFα levels and relative symptom 
u;71|bombm	!"ĺR2 linear = .21
R2 linear=0.21
ѵo=ѶՊ|ՊՊՍ SORRI ET AL.
before next ECT session. This finding differs from some previous re-
ports in which the TNFα level either increased, did not change, or de-
creased by ECT (First et al., 1996; Fluitman et al., 2011; Hestad et al., 
2003; Rotter et al., 2013; Rush et al., 2016; Zincir et al., 2016). The 
design of the study by Hestad et al. (Fluitman et al., 2011) somewhat 
u;v;l0Ѵ;v |_;7;vb]mo= |_;ru;v;m|v|7ĺ m |_;bu v|7ķ |_;$α 
level was measured during the ECT series at baseline and 1 hr after 
the first, fourth, and last ECT session. They reported a decrease in the 
baseline TNFα level during the ECT series and 24 hr and 1 week after 
|_;Ѵ-v|$v;vvbomŐѴb|l-m;|-ѴĺķƑƏƐƐőĺ77b|bom-ѴѴķ-7;1u;-v;bm
the TNFα level was observed in a study in which measurements were 
taken 1 day before the ECT series, at the time of the clinical response 
|o $ķ -m7 Ɛ7- -=|;u |_; v;ub;v Ő!v_ ;|-Ѵĺķ ƑƏƐѵőĺ m 1om|u-v|ķ
Fluitman et al. (Rotter et al., 2013) reported an immediate increase in 
the TNFα level after every single session of ECT but found no con-
stant change in the baseline TNFα level during the ECT series. The 
TNFα levels in these two latter studies were serum (not plasma) levels, 
making comparison with the present results difficult. Moreover, three 
studies found no change in the serum/plasma/plasma (respectively) 
TNFα level during and after the ECT series (First et al., 1996; Hestad 
et al., 2003; Zincir et al., 2016). However, in these studies, the timing 
of the blood samplings and procedures were somewhat different, ham-
pering comparison with the present results (First et al., 1996; Hestad 
et al., 2003; Zincir et al., 2016). Unfortunately, the post- ECT TNFα 
levels (e.g., 1 week after the series) were not available in the present 
study. However, if we would have observed a persistent decrease in 
the TNFα level after the ECT series, we would have presumed that 
this decrease was already apparent in the baseline measurements in 
different sessions during the ECT series.
	;1u;-v;v bm |_;$α level by anesthetics and muscle relaxant 
drugs (methohexital and succinylcholine) administered during ECT 
_-;0;;mu;rou|;7bmr-|b;m|vb|_		Ő"|;Ѵ_-ll;u;|-ѴĺķƑƏƐƐőĺ
Whether this decrease found in the present study in the TNFα level is 
related to the anesthetics used or the anti- inflammatory mechanisms 
of ECT are inconclusive and require further research.
llm;7vu;]Ѵ-|bom-m7-1|b-|bomo=|_;bm=Ѵ-ll-|ouu;vromv;
vv|;l -u; bmoѴ;7b|_		 ŐbѴѴ;u ;|-Ѵĺķ ƑƏƏƖőĺ ";;u-Ѵ v|7b;v
have reported elevated TNFα levels in the blood and cerebrospinal 




elevated TNF- α level has been somewhat associated with severe forms 
o=7;ru;vvbomŐmbvl-m;|-ѴĺķƐƖƖƖőĺmo|_;ul;|-Ŋ-m-Ѵvbvo=bm=Ѵ-l-
l-|ou0bol-uh;uv bmr-|b;m|vb|_		m7;u]obm]-m|b7;ru;vv-m|
treatment reported no decrease in the elevated baseline TNFα level. 
m|_-|u;rou|ķ_o;;uķ|_;u;-v-7;1u;-v;bm|_;$α level in re-
vrom7;uv1olr-u;7b|_momu;vrom7;uvŐक़_Ѵ;u;|-ѴĺķƑƏƐƕőĺ
The main limitation of the present study is the relatively small sam-
rѴ;vb;ĺ77b|bom-ѴѴķ|_;Ѵ-1ho=_;-Ѵ|_1om|uoѴv_-lr;u;7|_;bm|;u-
pretation of the results. Circulating TNFα levels are affected by various 
l;|-0oѴb1-m7r-|_oѴo]b1-Ѵ1om7b|bomvbm-77b|bom|o		Ő1u7Ѵ;ķ
bm1-m;ķ omm-]_|omķ 1ouuoķ ş !o1_;ķ ƑƏƐƒĸ "bm_- ;| -Ѵĺķ
2013). Moreover, plasma TNFα levels may be affected by anesthesia 
7ubm]$v;ub;vŐ"|;Ѵ_-ll;u;|-ѴĺķƑƏƐƐőĺ;m|_o]_|_;7b1_o|-
omized response correlated significantly with lower baseline TNFα 
levels, these levels predicted the dichotomized response only at trend 
level in the logistic regression model. The association should therefore 
be confirmed in a larger sample. The baseline (before any treatment) 
TNFα levels used here, however, reflect only the influence of the dis-
ou7;uŐ		őķmo||_;;==;1|o=$ĺ$_;v|u;m]|_vo=|_bvv|7bm1Ѵ7;
the standardized timing of repeated blood sampling during the individ-
ual ECT sessions and throughout the ECT series, which improves the 
u;Ѵb-0bѴb|o=|_;u;vѴ|vĺ$_vķ|_;;==;1|vo=0o|_|_;7bvou7;uŐ		ő
and the treatment (ECT) on TNFα levels have been considered.
m1om1ѴvbomķѴo$α levels before and after the first ECT ses-
sion predict symptom reduction after the ECT series. Every individual 
ECT session seemed to decrease the plasma TNFα level at 2 and 4 hr 
compared with baseline. This effect, however, was transitory because 
the baseline level did not change between the sessions. The predic-
tive value of the first ECT session TNFα levels associated with final 
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